🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic HSCT

RecruitingPhase 3Ages 18 Years - 100 YearsAllInstituto Nacional de Cancer, Brazil
NCT06071637 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Objective: To compare the effects of two low-power laser therapy protocols (application of a wavelength in the mouth, red region and another in the neck infrared region X simultaneous dual application of two wavelengths, red and infrared region in the mouth and neck) in the prevention of oral mucositis and oropharyngeal pain, dysphagia, TPN and opioid use in patients undergoing HSCT allogenic. Materials and methods: This is a phase III, double-blind, randomized study that will use LBP to prevent oral mucositis and oropharyngeal pain in two protocols with different dosimetry (divided into Group A and Group B). Patients will be included enrolled at the Bone Marrow Transplant Center - Cancer Hospital I - INCA, with indication of allogeneic HSCT, over 18 years old, able to cooperate with the treatment and perform the oral hygiene protocol, who present oral mucosa complete on the first day o

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with indication for allogeneic HSCT; * Patients over 18 years old; * Patients with intact oral mucosa on the first day of conditioning (D-7); * Patients able to cooperate with treatment; * Patients capable of performing the oral hygiene protocol; * Patients who agreed to participate in the study through the informed consent form (TCLE) in accordance with Resolution 466/12 of the National Health Council. Exclusion Criteria: * Patients who are receiving medication for the treatment and/or prevention of mucositis; * Patients who were not previously evaluated and released by INCA's Dentistry section team
💊

What it tests

  • Double low-power laser therapy simultaneous applicated
📍

Where

2 sites
Instituto Nacional de Cancer
Rio de Janeiro, Brazil
Instituto Nacional de Cancer
Rio de Janeiro, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy